TearLab launches consumer website for dry eye disease

TearLab (NASDAQ:TEAR; TSX:TLB) has launched “allaboutdryeye.com,” a new consumer website and social media program focused on supporting the company’s Accredited Dry Eye Centers program in North America. Allaboutdryeye.com was designed to help people suffering from dry eye disease (DED) by providing a place for them to share their experiences and ask questions, discover the science [...]

TearLab gets IGel reimbursement in Germany

TearLab (NASDAQ:TEAR; TSX:TLB) has received a unique, new “individual health benefits” or IGel code that applies to its osmolarity test for dry eye disease in Germany, effective immediately. IGel is the self-pay coding system that enables reimbursement for insured individuals. The system runs parallel to the state funding system and allows practitioners greater flexibility in [...]

TearLab U.S. patent expands testing beyond osmolarity

TearLab (NASDAQ:TEAR; TSX:TLB) has been granted a U.S. patent, entitled “Biomarker Normalization,” which gives the company broad and blocking intellectual property regarding the ability to compensate for first order dynamics in the eye, which is fundamental to accurate tear biomarker analysis, whether involving proteins, genes, or small molecules. The patent allows TearLab to build on [...]

COLA to accelerate adoption of TearLab dry eye test

TearLab (NASDAQ:TEAR; TSX:TLB) of San Diego has teamed up with COLA, a non-profit clinical laboratory education, consultation and accreditation organization, to help make the TearLab Osmolarity System for dry eye disease available in the U.S. at the point-of-care. The Centers for Medicare and Medicaid Services began reimbursement for the osmolarity test, effective Jan. 1, 2011, only [...]

TearLab gets osmolarity CPT code from AMA

The American Medical Association has published a new Current Procedural Terminology code that will apply to TearLab’s (NASDAQ:TEAR; TSX:TLB) osmolarity test for dry eye disease, effective Jan. 1, 2011. CPT codes are the most widely accepted form of medical nomenclature used to report medical procedures and services under public and private health insurance programs in [...]

TearLab receives U.S. patent for tear film collection and analysis

TearLab (NASDAQ:TEAR; TSX:TLB) was granted a U.S. patent for systems and methods of collecting tear film and measuring tear film osmolarity, which gives the company broad and blocking intellectual property regarding the measurement of genetic and protein biomarkers within the tear film. The patent, which will expire in 2029, allows TearLab to build on its [...]

CMS reports on TearLab osmolarity reimbursement

The Committee for Medicare and Medicaid Services (CMS) has published its recommended payment determination for new test codes, which includes a proposed reimbursement rate for TearLab’s (NASDAQ:TEAR; TSX:TLB) osmolarity test, effective January, 2011. The new Current Procedural Terminology code that will apply to the TearLab osmolarity test will be reimbursed by CMS at $24.01 (U.S.) [...]

You asked a CEO

Four weeks ago, we asked you what’s on your mind. Specifically, what would you like to “Ask a CEO?”  Frankly, we were heartened and surprised by your response. So as promised, this week’s Feature, which coincides with the first anniversary of biotuesdays.com’s launch, is a rundown of the questions and the answers we received. We [...]

In conversation with Marc Létourneau

Marc Létourneau is very well known among the senior management and boards of directors of many emerging growth companies.  An accomplished investment banker with over 20 years of experience providing strategic advice, raising capital and negotiating mergers and acquisitions in both domestic and international markets, he has played a key role in shaping the current [...]

« Previous Page